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Abstract
Background: Surgical attempts for locally recurrent rectal cancer often fail due to local re-
recurrence and distant metastasis. Preoperative chemoradiation may enhance better local control
and survival. The aim of this study was to assess the safety of oral uracil and tegafur (UFT) plus
leucovorin (LV), and irinotecan combined with radiation and determine the maximum-tolerated
dose (MTD) and dose limiting toxicity (DLT) of the triple drug regimen.
Patients and methods: Patients with locally recurrent rectal cancer received escalating doses of
irinotecan on days 1, 8, 15, and 22 (starting at 30 mg/m2, with 10 mg increments between
consecutive cohorts) and fixed doses of UFT (300 mg/m2) plus LV (75 mg/day) on days 3 to 7, 10
to 14, 17 to 21, and 24 to 28. Radiation was given 5 days per week totaling 40 to 50 Gy (2Gy/day).
Results:  Six patients were treated at the starting dose, and 2 received the full scheduled
chemoradiotherapy. The other 4 patients had grade 3 diarrhea and diarrhea was the DLT. One
patient had partial response and he had subsequently radical surgical resection. Median progression
free survival for local recurrence was 320 days.
Conclusion:  Irinotecan plus UFT/LV with concomitant radiotherapy in patients with locally
recurrent rectal cancer was not feasible due to diarrhea in this setting. Modification of the
treatment is needed.
Background
Local recurrence of rectal cancer is a formidable problem
after surgery for primary advanced rectal cancer. It has
been reported to be 5% to 30% after curative resection
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[1,2]. The prognosis for these patients is usually dismal in
terms of survival and quality of life. Twenty to 50 % of
these patients had local recurrence in the absence of dis-
tant metastasis [1,3]. In such patients, surgical interven-
tion is the best treatment choice for cure, however,
extended radical surgery including sacrectomy is often
required to obtain negative surgical margin [4-8]. In spite
of these aggressive attempts, the incidence of local re-
recurrence is still very high ranging from 30% to 70%
[5,6,9-11]. Multidisciplinary treatment approach is neces-
sary for better outcome.
In order to reduce local failure after surgery for primary
advanced rectal cancer, Heald has introduced total mes-
orectal excision (TME) [12]. The Dutch trial was designed
to evaluate the benefit of neoadjuvant therapy in addition
to TME. Subgroup analysis in the trial, preoperative radi-
otherapy could not improve local recurrence rate in
patients with a positive circumferential margin or in
patients requiring abdominoperineal resection [13]. Ger-
man study group demonstrated the usefulness of preoper-
ative chemoradiotherapy for locally advanced rectal
cancer to reduce local failure [14]. Gerard et al., [15]
(Fédération Française de Cancérologie 9203 trial) and
Bosset et al., [16] (EORTC 22921 trial) have also reported
decreased local failure rate by the addition of concurrent
chemotherapy in a neoadjuvant setting in comparison
with radiation only treatment. Many U.S. randomized tri-
als have indicated survival benefits for both chemother-
apy and concurrent chemoradiotherapy in the treatment
of rectal cancer [17,18]. Adding other chemotherapeutic
agents, which has been proven to improve the outcome in
advanced/metastatic disease, might potentially add to an
already proven curative benefit. There are a number of
new agents that have been developed for the treatment of
patients with colorectal cancer. Many trials with new
agents for concurrent radiotherapy are ongoing [19-23].
Several authors reported pilot studies of newer agents,
including capecitabine, UFT, oxaliplatin, irinotecan com-
bined with 5-FU and radiotherapy in the treatment of rec-
tal cancer. Mohiuddin et al., [24] recently published phase
II trial which indicated irinotecan and 5-FU in combina-
tion with radiotherapy have no better pathological com-
plete response (pCR) rate than infusional 5-FU and
radiotherapy as preoperative treatment in rectal cancer.
However, Mitchell et al reported good results in pCR rate
of preoperative chemoradiation therapy with irinotecan
and 5-FU [25].
Several trials regarding preoperative radiotherapy or
chemoradiotherapy for locally recurrent rectal cancer has
been reported as feasible and effective for improved
respectability [26-29]. Most of these studies, main chem-
otherapeutic agents are 5-fluorouracil (5-FU), mitomycin
C, and cisplatin. As complete pathologic response to pre-
operative therapy was predictive for an improved survival,
[29,30] and patients with locally recurrent rectal cancer
sometimes develop and die of distant metastasis, admin-
istration of effective and sufficient doses of active agents
concomitant with radiotherapy might improve survival.
Irinotecan has been shown to be effective in 5-FU refrac-
tory patients and irinotecan combined with 5FU showed
good results in metastatic and recurrent colorectal cancer.
Adding irinotecan to 5-FU with concomitant radiotherapy
may improve already proven curative effect of 5FU based
chemoradiation therapy of the local recurrent rectal can-
cer.
Irinotecan, oral tegafur/uracil (UFT), and leucovorin (LV)
might be expected to improve the local tumor regression
of radiotherapy without infusional 5-FU. Combined-
modality therapy with triple drugs and radiotherapy for
the local recurrence of rectal cancer has not been reported.
In the present study, we initiated a phase I trial to establish
a combination of triple drugs with concomitant radiother-
apy for locally recurrent rectal cancer.
Patients and methods
Eligibility and evaluation
This phase I trial was two-institutional prospective study.
Patients with locally recurrent rectal cancer were eligible
for entry onto this study. Additional inclusion criteria
were as follows: age 20–75 years, World Health Organiza-
tion (WHO) performance status of 0–1, adequate marrow
(12,000 ≥ leukocyte count ≥ 4,000/μL, platelet count ≥
100,000/μL), liver (AST/ALT < 100 U/L, total-bilirubin ≤
1.5 mg/dl), and renal (serum creatinin ≤ 1.5 mg/dl) func-
tion, and ability of oral intake. All patients provided writ-
ten informed consent. The protocol was reviewed and
approved by the institutional review board and the study
was performed according to the Declaration of Helsinki.
Patients were excluded if they have uncontrolled heart
failure, previous history of radiotherapy, prior malignant
disease, chronic diarrhea, and pregnancy or lactation. Pre-
treatment disease evaluation included physical examina-
tion, digital rectal examination, and sigmoidoscopy,
computed tomography of chest, abdomen, and pelvis,
and positron emission tomography in possible cases.
Study design and treatment plan
The primary objective of this study was to determine rec-
ommended irinotecan dose when combined with UFT, LV
and radiation therapy in patients with locally recurrent
rectal cancer by monitoring the dose-limiting toxicities
(DLTs) at each dose level. Secondary object of this study
was efficacy and overall survival.
Chemotherapy
The treatment consists of escalating doses of irinotecan as
a 90-minites infusion on day 1 of radiotherapy (RT) for 4World Journal of Surgical Oncology 2006, 4:83 http://www.wjso.com/content/4/1/83
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consecutive weeks (days 1,8,15 and 22). Patients received
UFT/LV orally 3 times a day (every 8 hours) for the days
3–7, 10–14, 17–21, 24–28, q5w. The dose of UFT and LV
were fixed at 300 mg/m2/day and 75 mg/body/day,
respectively, and starting dose of irinotecan was 30 mg/m2
(Figure 1). This dose represented 30% of the dose inten-
sity achieved with the recommended dose of 100 mg/m2,
and the dose was escalated of 10 mg/m2 in subsequent
groups of patients up to 70 mg/m2 to determine maxi-
mum tolerated dose (MTD). The doses of UFT and LV
were recommended dose of these two-drug combination
therapy. Three patients were initially enrolled at each dose
level. If none of these three experienced DLT (defined
later), then the next three patients were enrolled at the
next higher level. If one patient experienced DLT, then
three more patients were recruited at the same level. If no
more than one of six patients had DLT, then the next
cohort of patients was treated at the next level. If two or
more patients had DLT, then that level was considered to
MTD, and the level immediately preceding that level was
designated as the recommended dose (RD). Further five
patients were then enrolled at the RD to investigate the
toxicities and tolerability of that level. Patients were eval-
uated for toxicity weekly while on study, and all toxicities
were graded using the National Cancer Institute Common
Toxicity Criteria version 3.0. To avoid any bias relating to
GI adverse events, antiemetic prophylaxis were adminis-
trated to all patients
If a patient reported one of the following adverse events
on the day of planned irinotecan administration, chemo-
therapy was to be interrupted until adverse effect resolved
: leukopenia ≥ grade 2, neutropenia ≥ grade 2, platelets ≤
100000/μL, diarrhea ≥ grade 1, and other adverse events ≥
grade 3 (excluding alopecia, nausea, vomiting, fatigue,
and appetite loss). UFT/LV administration was withheld
in the event of grade 3 or 4 leukopenia and neutropenia,
platelets  ≤ 100000/μL, diarrhea ≥ grade 1, AST/ALT ≥
grade 2, stomatitis ≥ grade 2, and other adverse events ≥
grade 3 (excluding alopecia, nausea, vomiting, fatigue,
and appetite loss).
Radiotherapy
RT was delivered with a linear accelerator with using 10-
MV photons with anterior-posterior opposing field or
three-field technique consisting of a posterior and two lat-
eral fields. For three-dimensional treatment planning pur-
pose, all patients had a computed tomographic (CT) scan
in the treatment position. A planned irradiation was given
in daily fractions of 2.0 Gy, 5 days a week for 5 consecu-
tive weeks, resulting total dose of 40 to 50 Gy. The clinical
target volume (CTV) included the recurrent tumor with 1–
1.5 cm margin, sacrum, and the presacral space. The upper
border of the CTV was at the L5-S1 interspace. The lower
field border was 3 cm below the macroscopic tumor. Plan-
ning target volume (PTV) margin was 5 mm from the
CTV. Unless a patient had a following adverse events: leu-
kopenia ≥ grade3, neutropenia ≥ grade3, thrombocytope-
nia ≥ grade3, diarrhea ≥ grade 2, the irradiation was not
interrupted. In these occurrences, RT was withheld until
adverse events resolved.
Schema of treatment regimen Figure 1
Schema of treatment regimen.
Day
Radiotherapy
2.0 Gy/day
Oral UFT 300mg/m2
LV 75mg/body three 
times daily
CPT-11 30 mg/m2
90 min infusion 
escalation in 10mg/m2
1 8 15 22 29 36World Journal of Surgical Oncology 2006, 4:83 http://www.wjso.com/content/4/1/83
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Dose limiting toxicities
DLT was defined by the occurrence of one of the following
adverse events: 1) grade 4 hematologic toxicity, 2) any
grade 3 non-hematologic toxicity except for nausea and
vomiting. 3) RT cessation of ≥ one week, 4) cancellation
of irinotecan administration ≥ twice.
All the patients have been carefully followed by the radia-
tion oncologist and the surgeon. The follow-up ranges
from 650 to 721 days with a median follow-up of 697
days. Two patients had died and were followed until
death. Objective tumor response of locally recurrent mass
was assessed according to World Health Organization cri-
teria. Briefly, complete response (CR) was defined as the
complete disappearance of all recurrent tumors, partial
response (PR) as ≥ 50% reduction by the product of the
longest cross-diameters, stable disease (SD) as < 25%
reduction or increase and progressive disease (PD) as ≥
25% increase. Tumor size was determined by CT-PET
fusion images utilizing Standard Uptake Values [31]. The
status of distant metastases was not considered in this
study. In case of patients with surgical intervention, con-
firmation of a 4-week duration was not applied.
Results
Six patients were enrolled onto this two-institutional trial
between January 2004 and May 2004. Patient basic char-
acteristics are listed in Table 1
Toxicities
In the first enrollment, 3 patients were treated at level 1
between January and February 2004. Case 3, 66-year-old-
male, treatment had to be interrupted at day 18 because of
grade 3 diarrhea (with grade 1 abdominal pain). The
patient recovered within 1 week, so the rest of chemother-
apy was resumed. The other 2 patients did not have any
DLTs. We recruited then an additional three patients at the
same dose level. In these patients, all 3 patients had DLTs.
In one patient (case 4), therapy had to be discontinued
due to grade 3 diarrhea at day25 and bowel fistula requir-
ing surgical intervention. In another patient (case 5), he
had treatment interruption because of reversible grade 3
diarrhea (at day21) lasting for less than 7 days. The other
patient (case 6) had grade 3 diarrhea at day19 as well.
Of six patients treated on dose level I, four patients had
DLTs, including 4 patients with grade 3 diarrhea, and one
patient with bowel fistula which required surgical inter-
vention. Consequently dose escalation stopped at a dose
of 30 mg/m2, and diarrhea was considered as a DLT. All
adverse events are listed separately for the six patients in
Table 2.
Grade 2 or more hematological adverse events were
observed in 2 patients. One patient developed grade 3 leu-
kopenia, and one patients developed grade 2 leukopenia
lasting for less than 7 days, both of whom also developed
grade 2 neutropenia. Grade 2 anemia was observed in one
case. No blood transfusions were required during chemo-
radiotherapy. One patients who had bowel fistula devel-
oped grade 3 abdominal pain and grade 2 appetite loss
and nausea/vomiting.
The median percentage of given dose per planned chemo-
therapy of irinotecan and UFT delivered to patients was
100 % (mean; 95.8%) and 96.7 % (mean; 92.5%), respec-
tively.
Tumor response and survival
The response rate of the locally recurrent tumor was 17%.
There were one PR patient, 4 SD patients and one PD
patient. The patient with PR could proceed to surgical
resection of locally recurrent tumor with curative intent.
With a median follow-up of 697 days, two patients died.
Median progression free survival time of locally recurrent
tumor for 5 patients without operation was 320 days.
Median overall survival time has not been reached yet.
Discussion
There is no standard therapy for the treatment of locally
recurrent rectal cancer, especially for tumors such as those
fixed to the pelvic walls. External beam radiotherapy,
intraoperative radiotherapy, chemotherapy, and surgery
or combination of these modalities has been employed.
Table 1: Patient characteristics in 6 patients.
Case Age Sex Time to LR 
(months)
Initial surgery Recurrent site ECOG PS
#1 54 Male 9 AR Local 0
#2 55 Male 72 LAR Local 0
#3 66 Male 65 AR Local, lung 0
#4 62 Male 11 TPE Local, lung 0
#5 50 Male 22 LAR Local, lung 0
#6 56 Male 23 LAR Local, liver, LN 0
LR, local recurrence; ECOG, Eastern Cooperative Oncology Group; PS, performance status; AR, anterior resection; LAR, low anterior resection; 
TPE, total pelvic exenterationWorld Journal of Surgical Oncology 2006, 4:83 http://www.wjso.com/content/4/1/83
Page 5 of 7
(page number not for citation purposes)
These treatments gave certain results with 5-year survival
between 20% to 50%, however systematic treatment strat-
egy still remains to be established. Patients with locally
recurrent rectal cancer have been routinely included in
published phase I and II trials of chemoradiation therapy,
and curative outcome in these patients has been previ-
ously reported. Mohiuddin et al., reported the prognostic
significance of post chemoradiation pathologic stage fol-
lowing preoperative chemoradiation for recurrent rectal
cancer patient who were treated with bolus/continuous
5FU combined with radiation therapy [32]. In the treat-
ment of metastatic colorectal cancer, irinotecan has been
shown to be effective, so we hypothesize preoperative iri-
notecan, UFT and concurrent radiotherapy might improve
tumor regression and potentially have survival benefits
compared to currently available chemoradiation regimen
in the rectal cancer patients with local failure.
Firstly, we have tried to determine recommended dose of
irinotecan with concomitant radiotherapy, when UFT and
LV doses were fixed. Irinotecan is a promising chemother-
apy agent and is also a new class of chemotherapeutic
radiation sensitizer [25,33]. We did not administer UFT
and CPT-11 simultaneously because simultaneous
administration of 5-FU and CPT-11 might have the small
chance of severe GI toxicity. Shimada et al., reported unex-
pected mild toxicity in the combined CPT-11 and 5-FU
regimen [34]. Sasaki et al., reported pharmacokinetic
interaction of 5FU and CPT-11 which showed the plasma
concentration or AUC of CPT-11 was higher in the com-
bined CPT-11 and 5FU regimen than in the CPT-11 alone
regimen [35].
We have reported that separate administration of CPT-11
and UFT in this regimen did not alter the pharmacokinet-
ics of SN-38, a major active metabolite of CPT-11 [36]. As
we considered CPT-11 as the key drug to enhance the
effect of radiation in this regimen, we gave CPT-11 on the
beginning day of radiation therapy. Therefore, UFT was
not administered concurrently on radiotherapy days in
this study.
A total of 6 patients were entered onto the study. On dose
level I, 4 of 6 patients developed grade 3 diarrhea, which
was accompanied by grade 3 leukopenia and abdominal
pain in one patient. In this patient, bowel fistula had
occurred and subsequently surgical intervention was
required. As we encountered DLT on dose level I, we have
discussed about whether we should recruit patients on
dose level 0, irinotecan 20 mg/m2. As irinotecan 20 mg/
m2, one fifth dose of recommended dose of monotherapy
in Japan, might be too low to have biological activity for
metastatic region outside the radiation fields, we have
chosen to use different chemotherapy schedule to exam-
ine the recommended dose of irinotecan with UFT/LV in
combination with radiotherapy. As grade 3 diarrhea
occurred around the 3rd week, we modified the treatment
schedule to put chemotherapy-rest during the third week,
and oral UFT/LV were to be administered on the same day
of radiation to make complete chemoradiatherapy-free
days. We have reached DLT at a low dose of irinotecan.
Japanese patients are susceptible to have irinotecan
induced GI toxicity, especially diarrhea. Maximum
approved weekly dose of irinotecan alone in Japan is 100
mg/m2 which is much lower than European/American
dose [37].
Table 2: Maximum severity of adverse events in each 6 patients.
NCI-CTC grade
Case#
#1 #2 #3 #4 #5 #6
Hematological
L e u k o p e n i a 000302
N e u t r o p e n i a 001202
A n e m i a 111210
Thrombocytop
enia
000000
Gastrointestinal
Appetite loss 1 1 1 2 1 0
D i a r r h e a 013333
Nausea/
vomiting
110210
A b d o m i n a l  p a i n 111312
Grade 3 diarrhea occurred at day 18 (#3), 25 (#4), 21 (#5), and 19 (#6)
Case #4 had bowel fistula which required surgical intervention.World Journal of Surgical Oncology 2006, 4:83 http://www.wjso.com/content/4/1/83
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In the present study, treatment response of 6 patients was
not favorable according to the WHO criteria. However, in
one patient, surgical resection was performed 4 weeks
after this chemoradiotherapy because of prominent
tumor regression, otherwise he was inoperable. This
patient underwent super low anterior resection with high
sacral bone resection for curative intent.
5-FU, leucovorin, cisplatin, and mitomycin C have been
used in combination with radiotherapy for the purpose of
radio-sensitizer. Their regimens were feasible and no
severe toxicities were reported [26,27,37,38]. UFT plus
leucovorin and radiation have been extensively investi-
gated in both primary advanced or recurrent rectal cancer
[39-41]. DLT was diarrhea as in this study, and recom-
mended dose for the concomitant radiation was 350 mg/
m2/day UFT + 90 mg LV [39,40]. In the recent years,
capecitabine, irinotecan, and oxaliplatin have been used
for primary advanced or inoperable rectal cancer [42-44].
Mohiuddin  et al., reported randomized phase II trial
which showed that combining irinotecan (50 mg/m2)
and 5-FU with radiotherapy was tolerable and efficacious
[24]. In contrast to the study, we have reached DLT at a
low dose of irinotecan (30 mg/m2). Japanese patients are
susceptible to have irinotecan induced GI toxicity, espe-
cially diarrhea. Maximum approved weekly dose of iri-
notecan alone in Japan is 100 mg/m2 which is much lower
than European/American dose [45]. These combined
modality have achieved clear resection margins and
tumor "downstaging", and thus may improve long-term
local control and survival rate [27,28,37,43]. However,
combined-modality therapy of the triple drugs with radi-
otherapy for the local recurrence of rectal cancer has not
been reported. A progress in our regimen might have high
remission rate and may establish a chemoradiotherapy as
a preoperative treatment for the patients with locally
recurrent rectal cancer.
Summary
This study was not able to demonstrate the feasibility of
irinotecan, UFT/LV with concomitant radiotherapy in
patients with locally recurrent rectal cancer due to
diarrhea. We are now investigating this triple-drug regi-
men with modified treatment schedule. Further insight
into treatment schedule and patient management after
surgery may establish a safer and effective treatment for
the locally recurrent rectal cancer.
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